Literature DB >> 11130078

A Toll-like receptor recognizes bacterial DNA.

H Hemmi1, O Takeuchi, T Kawai, T Kaisho, S Sato, H Sanjo, M Matsumoto, K Hoshino, H Wagner, K Takeda, S Akira.   

Abstract

DNA from bacteria has stimulatory effects on mammalian immune cells, which depend on the presence of unmethylated CpG dinucleotides in the bacterial DNA. In contrast, mammalian DNA has a low frequency of CpG dinucleotides, and these are mostly methylated; therefore, mammalian DNA does not have immuno-stimulatory activity. CpG DNA induces a strong T-helper-1-like inflammatory response. Accumulating evidence has revealed the therapeutic potential of CpG DNA as adjuvants for vaccination strategies for cancer, allergy and infectious diseases. Despite its promising clinical use, the molecular mechanism by which CpG DNA activates immune cells remains unclear. Here we show that cellular response to CpG DNA is mediated by a Toll-like receptor, TLR9. TLR9-deficient (TLR9-/-) mice did not show any response to CpG DNA, including proliferation of splenocytes, inflammatory cytokine production from macrophages and maturation of dendritic cells. TLR9-/- mice showed resistance to the lethal effect of CpG DNA without any elevation of serum pro-inflammatory cytokine levels. The in vivo CpG-DNA-mediated T-helper type-1 response was also abolished in TLR9-/- mice. Thus, vertebrate immune systems appear to have evolved a specific Toll-like receptor that distinguishes bacterial DNA from self-DNA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11130078     DOI: 10.1038/35047123

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  1800 in total

Review 1.  Nucleic acid vaccines: tasks and tactics.

Authors:  B S McKenzie; A J Corbett; J L Brady; C M Dyer; R A Strugnell; S J Kent; D R Kramer; J S Boyle; A M Lew
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 2.  Activation of the immune system by bacterial CpG-DNA.

Authors:  Georg Häcker; Vanessa Redecke; Hans Häcker
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

3.  Receptor-mediated endocytosis of phosphodiester oligonucleotides in the HepG2 cell line: evidence for non-conventional intracellular trafficking.

Authors:  Philippe de Diesbach; Francisca N'Kuli; Catherine Berens; Etienne Sonveaux; Michel Monsigny; Annie-Claude Roche; Pierre J Courtoy
Journal:  Nucleic Acids Res       Date:  2002-04-01       Impact factor: 16.971

4.  Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells.

Authors:  Anne-Sophie Beignon; Jean-Paul Briand; Sylviane Muller; Charalambos D Partidos
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

Review 5.  Toll receptors: a central element in innate immune responses.

Authors:  Thierry Vasselon; Patricia A Detmers
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

Review 6.  Lipopolysaccharide endotoxins.

Authors:  Christian R H Raetz; Chris Whitfield
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

7.  Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus.

Authors:  Sang-Moo Kang; Richard W Compans
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 8.  Discovery of immunopotentiatory drugs: current and future strategies.

Authors:  J Rhodes
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

9.  'Immunomers'--novel 3'-3'-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Dong Yu; Ekambar R Kandimalla; Lakshmi Bhagat; Jin-Yan Tang; Yanping Cong; Jimmy Tang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2002-10-15       Impact factor: 16.971

10.  Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice.

Authors:  Tie Liu; Tetsuya Matsuguchi; Naotake Tsuboi; Toshiki Yajima; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.